A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition

A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition

A vesicular stomatitis virus (VSV)-based assay enables high-throughput screening for small molecular protease inhibitors that can block viral proteases, like the Mpro/3CLpro/Nsp5 in SARS-CoV-2.

Bibliographic Details
Main Authors:	Emmanuel Heilmann, Francesco Costacurta, Stephan Geley, Seyad Arad Mogadashi, Andre Volland, Bernhard Rupp, Reuben Stewart Harris, Dorothee von Laer
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-04-01
Series:	Communications Biology
Online Access:	https://doi.org/10.1038/s42003-022-03277-0

Similar Items

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.
by: Francesco Costacurta, et al.
Published: (2024-09-01)

Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro/3CLpro in Living Cells
by: Seyed Arad Moghadasi, et al.
Published: (2022-06-01)

A Gaussia luciferase reporter assay for the evaluation of coronavirus Nsp5/3CLpro activity
by: Asimenia Vlachou, et al.
Published: (2024-09-01)

Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir
by: Laura Krismer, et al.
Published: (2024-06-01)

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
by: Janine Kimpel, et al.
Published: (2018-03-01)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
by: Yi Kuang, et al.
Published: (2023-04-01)

Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase
by: Mikolaj Zmudzinski, et al.
Published: (2023-06-01)

Exploring Possible Drug-Resistant Variants of SARS-CoV‑2 Main Protease (Mpro) with Noncovalent Preclinical Candidate, Mpro61
by: Jessica R. Kenneson, et al.
Published: (2025-01-01)

Crystallographic models of SARS-CoV-2 3CLpro: in-depth assessment of structure quality and validation
by: Mariusz Jaskolski, et al.
Published: (2021-03-01)

Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2
by: Juliana C. Ferreira, et al.
Published: (2020-12-01)

Progress in Research on Inhibitors Targeting SARS-CoV‑2 Main Protease (Mpro)
by: Yue Yang, et al.
Published: (2024-08-01)

Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
by: Agnieszka Zagórska, et al.
Published: (2024-07-01)

The temperature-dependent conformational ensemble of SARS-CoV-2 main protease (Mpro)
by: Ali Ebrahim, et al.
Published: (2022-09-01)

Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro)
by: Soumya Gulab Katre, et al.
Published: (2022-06-01)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
by: Katarzyna Papaj, et al.
Published: (2022-01-01)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease.
by: Katarzyna Papaj, et al.
Published: (2022-01-01)

The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
by: Svetlana V. Belenkaya, et al.
Published: (2023-06-01)

Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants.
by: André Volland, et al.
Published: (2021-10-01)

Corrigendum: The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper
by: Svetlana V. Belenkaya, et al.
Published: (2023-11-01)

Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
by: Vicky Mody, et al.
Published: (2021-01-01)

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences
by: Rohan R. Narkhede, et al.
Published: (2020-06-01)

In Silico Drug Repurposing of Penicillins to Target Main Protease Mpro of SARS-CoV-2
by: Baby Krishnaprasad, et al.
Published: (2020-11-01)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
by: Catherine Dold, et al.
Published: (2016-01-01)

The viral vector vaccine VSV-GP boosts immune response upon repeated applications
by: Tober R, et al.
Published: (2012-09-01)

Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design
by: Wei Yu, et al.
Published: (2021-12-01)

Insilico generation of novel ligands for the inhibition of SARS-CoV-2 main protease (3CLpro) using deep learning
by: Prejwal Prabhakaran, et al.
Published: (2023-06-01)

The Methyltransferase Region of Vesicular Stomatitis Virus L Polymerase Is a Target Site for Functional Intramolecular Insertion
by: Emmanuel Heilmann, et al.
Published: (2019-10-01)

Protegrin-2, a potential inhibitor for targeting SARS-CoV-2 main protease Mpro
by: Zainab Jan, et al.
Published: (2023-01-01)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
by: Karen Anbro Gammeltoft, et al.
Published: (2023-09-01)

Natural phenolic compounds from Satureja L. as inhibitors of COVID-19 protease (Mpro): Computational investigations
by: Faika Başoğlu-Ünal, et al.
Published: (2022-01-01)

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
by: Qing Hu, et al.
Published: (2022-09-01)

A genetically encoded BRET-based SARS-CoV-2 Mpro protease activity sensor
by: Anupriya M. Geethakumari, et al.
Published: (2022-09-01)

Towards potential inhibitors of COVID-19 main protease Mpro by virtual screening and molecular docking study
by: Moujane Soumia, et al.
Published: (2020-01-01)

In silico exploration of Lycoris alkaloids as potential inhibitors of SARS-CoV-2 main protease (Mpro)
by: Fredrick Mutie Musila, et al.
Published: (2022-09-01)

Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?
by: Matteo Pavan, et al.
Published: (2022-12-01)

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
by: Anoop Narayanan, et al.
Published: (2022-02-01)

3CLpro inhibitors: DEL-based molecular generation
by: Feng Xiong, et al.
Published: (2022-12-01)

PREDIKSI SENYAWA EUCALYPTUS SEBAGAI INHIBITOR POTENSIAL COVID-19 MAIN PROTEASE (Mpro) SECARA MOLECULAR DOCKING
by: Muhammad Fauzi, et al.
Published: (2021-05-01)

Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814
by: Haihai Jiang, et al.
Published: (2023-08-01)

In Silico Study of Secondary Metabolites in Dendrobium spp. as SARS-CoV-2 Antivirus on Main Protease (Mpro)
by: Anggiresti Kinasih, et al.
Published: (2022-03-01)